Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The serine/threonine protein kinase pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted pipeline therapeutics report provides comprehensive information on the serine/threonine protein kinase pim 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in serine/threonine protein kinase pim 2 targeted therapeutics development with respective active and dormant or discontinued projects.
What are the key indications in the serine/threonine protein kinase pim 2 targeted pipeline market?
Some of the key indications in the serine/threonine protein kinase pim 2 targeted pipeline market are hematological tumor, acute myelocytic leukemia (AML, acute myeloblastic leukemia), myelofibrosis, acute lymphocytic leukemia (ALL, acute lymphoblastic leukemia), bladder cancer, breast cancer, chronic lymphocytic leukemia (CLL), colon cancer, diffuse large B-cell lymphoma, and liver cancer.
Serine/threonine protein kinase pim 2 targeted pipeline market, by indications
For more indication insights, download a free sample
Which are the key companies in the serine/threonine protein kinase pim 2 targeted pipeline market?
The key companies in the serine/threonine protein kinase pim 2 targeted pipeline market are Amgen Inc, Incyte Corp, Inflection Biosciences Ltd, NewBay Medical Technology Co Ltd, Novartis AG, Sanofi, Sumitomo Dainippon Pharma Oncology, Inc, Yakult Honsha Co Ltd, and Zovis Pharmaceuticals.
Amgen Inc
Amgen Inc (Amgen) is a biotechnology company which discovers, develops, manufactures and markets innovative human therapeutics to treat patients suffering from serious diseases. It develops novel medicines in six focused therapeutic areas including cardiovascular disease, oncology/hematology, inflammation, bone health, neuroscience and nephrology. The company develops products by using advanced human genetics to unravel the difficulties of disease and understand the fundamentals of human biology.
Incyte Corp
Incyte Corp (Incyte) is a biopharmaceutical company, which discovers, develops and commercializes proprietary cancer therapeutics. The company’s lead product, Jakafi (ruxolitinib) is marketed in the US for the treatment of patients with high-risk myelofibrosis; and polycythemia vera who are intolerant to hydroxyurea. The company distributes Jakafi through a network of specialty pharmacy providers and wholesalers. In collaboration with Incyte, Novartis International Pharmaceutical Ltd (Novartis) develops and commercializes ruxolitinib outside the US for hematologic and cancer indications under the name Jakavi.
Inflection Biosciences Ltd
Inflection Biosciences Ltd (Inflection Biosciences) is a drug development company focused on the discovery and development of small molecule therapeutics for the treatment of cancer. The company’s pipeline products include dual mechanism kinase inhibitors and pim kinase inhibitors including IBL-300, IBL-202 and IBL-100.
Serine/threonine protein kinase pim 2 targeted pipeline market, by key companies
To know more about key companies, download a free sample
Market overview
Key indications | Hematological Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Myelofibrosis, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Bladder Cancer, Breast Cancer, Chronic Lymphocytic Leukemia (CLL), Colon Cancer, Diffuse Large B-Cell Lymphoma, and Liver Cancer |
Key companies | Amgen Inc, Incyte Corp, Inflection Biosciences Ltd, NewBay Medical Technology Co Ltd, Novartis AG, Sanofi, Sumitomo Dainippon Pharma Oncology, Inc, Yakult Honsha Co Ltd, and Zovis Pharmaceuticals |
Scope
- The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1)
- The report reviews Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope”
Incyte Corp
Inflection Biosciences Ltd
NewBay Medical Technology Co Ltd
Novartis AG
Sanofi
Sumitomo Dainippon Pharma Oncology, Inc
Yakult Honsha Co Ltd
Zovis Pharmaceuticals
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key indications in the serine/threonine protein kinase pim 2 targeted pipeline market?
Hematological tumor, acute myelocytic leukemia (AML, acute myeloblastic leukemia), myelofibrosis, acute lymphocytic leukemia (ALL, acute lymphoblastic leukemia), bladder cancer, breast cancer, chronic lymphocytic leukemia (CLL), colon cancer, diffuse large B-cell lymphoma, and liver cancer are the key indications in the serine/threonine protein kinase pim 2 targeted pipeline market.
-
Which are the key companies in the serine/threonine protein kinase pim 2 targeted pipeline market?
Amgen Inc, Incyte Corp, Inflection Biosciences Ltd, NewBay Medical Technology Co Ltd, Novartis AG, Sanofi, Sumitomo Dainippon Pharma Oncology, Inc, Yakult Honsha Co Ltd, and Zovis Pharmaceuticals are the key companies in the serine/threonine protein kinase pim 2 targeted pipeline market.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.